←Back to Expert Scholars
Translational Medicine / 转化医学NUT Carcinoma and Head and Neck
Joshua Bauml
MD
🏢Janssen Research and Development🌐USA
Senior Director, Clinical Research
45
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Joshua Bauml contributed to early BET inhibitor clinical trials for NUT midline carcinoma and has been an investigator across head and neck and thoracic rare cancer programs. He now leads oncology drug development at Janssen.
Share:
🧪Research Fields 研究领域
NUT carcinoma
BET inhibitors
head and neck oncology
thoracic oncology
clinical trials
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Joshua Bauml 的研究动态
Follow Joshua Bauml's research updates
留下邮箱，当我们发布与 Joshua Bauml（Janssen Research and Development）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment